Like protein powder and creatine, pre-workout is a staple for fitness enthusiasts worldwide. In fact, 78 percent of regular ...

Biogen has bagged $250 million to advance a key pipeline prospect. Royalty Pharma is providing the cash to bankroll phase 3 development of a lupus candidate that Biogen has named in a bunch of ...

Aspire Biopharma (ASBP) announced plans to launch a single dose pre-workout supplement utilizing Aspire’s patent-pending and proprietary ...

New product expected to set a new standard for potency and performance in the estimated $20 billon pre-workout marketDesert Stream Inc., a ...

Biogen is continuing to thin its pipeline, dropping a phase 2 program acquired in the $7.3 billion Reata Pharmaceuticals buyout and kicking early-stage Alzheimer’s and Parkinson’s prospects ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access information on a device and to provide personalised ads and content, ad and ...

Biogen (NASDAQ:BIIB) shares traded flat in the premarket on Wednesday after the Alzheimer’s drug developer reported better-than-expected Q4 2024 financials while its full-year outlook ...

Biogen's Q4 2024 earnings showed slight revenue growth but Wall Street remains unimpressed due to weak guidance and declining key drug franchises. Leqembi's commercial performance is disappointing ...

Forecasts 2025 profit below expectations Signs $250 million deal for lupus drug funding Shares drop more than 6% in early trading Feb 12 (Reuters) - Biogen (BIIB.O), opens new tab on Wednesday ...

Biogen expects full-year 2025 total revenue to decline by a mid-single digit percentage. The company’s stock was down about 6% at 10 a.m. on Wednesday with shares priced at around $131 apiece.

We think Biogen's neurology, immunology, and focus on rare diseases support a narrow moat. Biogen's strategy has its roots in the 2003 merger of Biogen (Avonex for treating multiple sclerosis ...

Biogen posted Q4 adjusted EPS of $3.44, up 17%, beating the $3.35 consensus. Sales rose to $2.46B, surpassing estimates. Biogen forecasts 2025 EPS of $15.25-$16.25, below the $16.34 consensus ...